ng101
(2)
Neurogastrx, Inc.
Neurogastrx is a Woburn, Massachusetts biopharmaceutical company developing therapies for gastrointestinal disorders rooted in the enteric nervous system. Its lead candidate, NG101, is an oral, peripherally acting dopamine D2 receptor antagonist (a proprietary mesylate salt of metopimazine) in late-stage development for gastroparesis and for the nausea and vomiting that limit GLP-1 weight-loss and diabetes drugs. Backed by roughly $105-125M from OrbiMed, 5AM Ventures and venBio, the company reported Phase 2 data in 2025 showing sizable reductions in GLP-1-induced nausea and vomiting.
James O'Mara
James (Jim) O'Mara is the President and CEO of Neurogastrx, a Woburn, Massachusetts specialty pharmaceutical company developing oral therapies for gastrointestinal disorders. A pharmacist by training with decades in biotech, he was one of the original members of the LINZESS team at Ironwood Pharmaceuticals, where he rose to Senior Vice President of Corporate Development and drove licensing deals across the U.S., Europe, Japan and China. At Neurogastrx he raised a $60 million Series B and is steering the company's lead candidate, NG101, through clinical studies aimed at the nausea and vomiting that lead many patients to abandon GLP-1 weight-loss and diabetes medicines.